We have a second retraction from a group of neuroscience researchers in Belgium who discovered fatal errors in their work on how the brain sets about the task of reading written language. Spoiler alert: Turns out those errors weren’t errors after all.
Two researchers in Denmark are guilty of scientific dishonesty, the Danish Committees on Scientific Dishonesty (DCSD, Danish acronym UVVU) has concluded.
We’re always glad to have guest posts, and here’s one from François-Xavier Coudert, reporting from France.
As we reported the other day, a Nature editorial suggested that police involvement might be an appropriate response to research misconduct. The French seem to agree, based on reports in the media there, as Coudert writes:
Nearly six months after first expressing concern about the validity of a 2010 paper on multiple sclerosis, Nature Medicine has retracted the article for containing “erroneous” data — which in this case don’t seem to have existed, making them more fabricated than wrong.
The paper, “Crucial role of interleukin-7 in T helper type 17 survival and expansion in autoimmune disease,” came from a group led by Jingwu Zhang, who at the time ran GlaxoSmithKline’s Research and Development Center in Shanghai.
The Journal of Clinical Anesthesia has a retraction of a 2006 paper by a group from Columbia University that, to our minds, is the poster child for how not to handle such things.
The article, “Dexmedetomidine infusion is associated with enhanced renal function after thoracic surgery,” was written by Robert J. Frumento, Helene G. Logginidou, Staffan Wahlander, Gebhard Wagener, Hugh R. Playford and Robert N. Sladen, who now is chief of critical care at the institution. The paper has been cited 30 times, according to Thomson Scientific’s Web of Knowledge.
The Lancet has retracted a study of Novartis’ blood pressure drug valsartan (Diovan) that has been subject to an investigation following the retraction of a related study earlier this year.
Bente Klarlund Pedersen, a University of Copenhagen researcher, has published with Milena Penkowa, four of whose papers have been retracted following investigations. In the press, she argued that while she had made mistakes, she had not committed misconduct.
An Australian university has put a hold on trials of an experimental drug for skin cancer whose main developer has been dogged by charges of research misconduct for several years.
The Australian Broadcasting Corporation is reporting that the University of New South Wales has suspended trials of the drug, DZ13, while it investigates the work of Levon Khachigian, who is leading the studies.
According to the news organization, Khachigian and his group were cleared by the school in two prior inquiries. However, additional accusations of misconduct — specifically involving image manipulation and misuse — prompted a third investigation.
We’ve found four retractions of Khachigian’s studies, from the Journal of Biological Chemistry and Biochemical and Biophysical Research Communications, between 2009 and 2010 (before the launch of Retraction Watch).
Milena Penkowa, the Danish neuroscientist who resigned from the University of Copenhagen in December 2010 amid suspicions of misconduct, has had another paper retracted.